Phase II study of oral methyl CCNU and prednisone in previously treated alkylating agent resistant multiple myeloma

K. Tornyos, H. Silberman, Alan Solomon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper. Methyl-CCNU was given orally before breakfast at 6-wk intervals at a starting dose of 50 mg/m2 with the intention of increasing the dose to 100, 150, and 200 mg/m2 with each subsequent course. The dose of prednisone was 75 mg/day X 7 with each course. The response rate was 46% (six of 13 patients). No patient had better than a fair response. Drug toxicity, severe enough to prevent further dose escalation, was observed in every case. Prior BCNU therapy or the lack of response to previous alkylating agents did not prevent a response to methyl-CCNU + prednisone. The response rate of methyl-CCNU + prednisone in MM is comparable to the results achieved with other agents in similar groups of patients.

Original languageEnglish (US)
Pages (from-to)785-787
Number of pages3
JournalCancer Treatment Reports
Volume61
Issue number5
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Semustine
Alkylating Agents
Prednisone
Multiple Myeloma
Carmustine
Breakfast
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase II study of oral methyl CCNU and prednisone in previously treated alkylating agent resistant multiple myeloma. / Tornyos, K.; Silberman, H.; Solomon, Alan.

In: Cancer Treatment Reports, Vol. 61, No. 5, 01.12.1977, p. 785-787.

Research output: Contribution to journalArticle

@article{68ed51bc160643eeaaade2cbb902941f,
title = "Phase II study of oral methyl CCNU and prednisone in previously treated alkylating agent resistant multiple myeloma",
abstract = "Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper. Methyl-CCNU was given orally before breakfast at 6-wk intervals at a starting dose of 50 mg/m2 with the intention of increasing the dose to 100, 150, and 200 mg/m2 with each subsequent course. The dose of prednisone was 75 mg/day X 7 with each course. The response rate was 46{\%} (six of 13 patients). No patient had better than a fair response. Drug toxicity, severe enough to prevent further dose escalation, was observed in every case. Prior BCNU therapy or the lack of response to previous alkylating agents did not prevent a response to methyl-CCNU + prednisone. The response rate of methyl-CCNU + prednisone in MM is comparable to the results achieved with other agents in similar groups of patients.",
author = "K. Tornyos and H. Silberman and Alan Solomon",
year = "1977",
month = "12",
day = "1",
language = "English (US)",
volume = "61",
pages = "785--787",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Phase II study of oral methyl CCNU and prednisone in previously treated alkylating agent resistant multiple myeloma

AU - Tornyos, K.

AU - Silberman, H.

AU - Solomon, Alan

PY - 1977/12/1

Y1 - 1977/12/1

N2 - Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper. Methyl-CCNU was given orally before breakfast at 6-wk intervals at a starting dose of 50 mg/m2 with the intention of increasing the dose to 100, 150, and 200 mg/m2 with each subsequent course. The dose of prednisone was 75 mg/day X 7 with each course. The response rate was 46% (six of 13 patients). No patient had better than a fair response. Drug toxicity, severe enough to prevent further dose escalation, was observed in every case. Prior BCNU therapy or the lack of response to previous alkylating agents did not prevent a response to methyl-CCNU + prednisone. The response rate of methyl-CCNU + prednisone in MM is comparable to the results achieved with other agents in similar groups of patients.

AB - Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper. Methyl-CCNU was given orally before breakfast at 6-wk intervals at a starting dose of 50 mg/m2 with the intention of increasing the dose to 100, 150, and 200 mg/m2 with each subsequent course. The dose of prednisone was 75 mg/day X 7 with each course. The response rate was 46% (six of 13 patients). No patient had better than a fair response. Drug toxicity, severe enough to prevent further dose escalation, was observed in every case. Prior BCNU therapy or the lack of response to previous alkylating agents did not prevent a response to methyl-CCNU + prednisone. The response rate of methyl-CCNU + prednisone in MM is comparable to the results achieved with other agents in similar groups of patients.

UR - http://www.scopus.com/inward/record.url?scp=0017755635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017755635&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 785

EP - 787

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -